In the year 2000, Alkem launched its first Mass Marketing Division/ Generics division- Futura. Among the 19 divisions in Alkem,Futura is the second largest division. Two brands of the division – Omee and Almox have both crossed the landmark sales of 100 Crs. In fact both brands feature among the top 10 brands of Alkem with Omee at the 7th and Almox at the 8th rank.
In 2013, Alkem unveiled another generics division- Maxxio. The division aimed to introduce wellness products with elegant and appealing packaging.
In four years’ time Maxxio crossed 75 Crs. with brands like Lycolyfe & Orogard being well established across the country.
Started in 1999-2000 with modest sales figures of 5 Crs in the launch year, Futura and Maxxio divisions of Alkem generics have been taking giant strides year after year with a sales revenue of 850 Cr in 2016-17.
Alkem has established itself as a landmark name in high-quality branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals production.
Alkem Laboratories Limited was incorporated in 1973 by founders Mr. Samprada Singh and Mr. Basudeo Singh. Coming from a family of farmers, the founder’s entry into the pharmaceutical industry is attributed to the successive droughts in Bihar that prompted them to pursue a career away from agriculture. From then on there was no looking back for these zealous entrepreneurs. The first plant was set up in 1978 in Taloja, Mumbai. Today Alkem owns and operates 14 manufaturing facilities across five locations in India and two manufacturing facilities in the United States.
With a comprehensive portfolio of over 700 brands covering all the major therapeutic segments and a robust pan-India sales and distribution network
Alkem has been amongst the top ten pharmaceutical companies in India in terms of domestic sales for the past 13 years. Alkem has been ranked the No.1 Anti-infective company in India for the past 10 years and features amongst the leading pharmaceutical companies in the therapeutic segments of Gastro-intestinal, Pain management and Vitamins / Minerals / Nutrients.
Research & Development constitute a core part of the growth strategy at Alkem.The company has four R&D facilities- two in India and two in the U.S. where more than 500 scientists work on various drug development.
In 2015 Alkem successfully completed its Initial Public Offering (IPO) and its equity shares were listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. The issue saw a robust response across investor categories and was overall subscribed to the extent of 44.29 times. This was the largest ever demand generation by a pharmaceutical company in India through IPO/QIP
To achieve value driven leadership in the Health care industry through Quality that is infinite, Service that is admired and Hard work that endures.
Cluster of Futura & Maxxio divisions to cross a landmark turnover of 2020Crs by the year 2020.
2019 © Alkem Labs. All Rights Reserved